UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Hexavalent vaccines: increasing options for policy-makers and providers. A review of the data supporting interchangeability (substitution with vaccines containing fewer antigens) and mixed schedules from the same manufacturer

Expert review of vaccines, 2018-06, Vol.17 (6), p.513-524

2018

Volltextzugriff (PDF)

Treatment Preferences in Young Adults with Moderate to Severe Psoriasis: A Qualitative Study from the Nordic Countries

Dermatology and therapy, 2023-08, Vol.13 (8), p.1873-1887

2023

Volltextzugriff (PDF)

Certolizumab Pegol for the Treatment of Plaque Psoriasis in Routine Clinical Practice: One-Year Results from the CIMREAL Study

Dermatology and therapy, 2024-08, Vol.14 (8), p.2077-2092

2024

Volltextzugriff (PDF)

Correction: Certolizumab Pegol for the Treatment of Plaque Psoriasis in Routine Clinical Practice: One-Year Results from the CIMREAL Study

Dermatology and therapy, 2024-10, Vol.14 (10), p.2923-2926

2024

Volltextzugriff (PDF)

Long-Term Health-Related Quality of Life in Patients with Plaque Psoriasis Treated with Certolizumab Pegol: Three-Year Results from Two Randomised Phase 3 Studies (CIMPASI-1 and CIMPASI-2)

Dermatology and therapy, 2023-01, Vol.13 (1), p.315-328

2023

Volltextzugriff (PDF)

Publisher Correction: Long-Term Health-Related Quality of Life in Patients with Plaque Psoriasis Treated with Certolizumab Pegol: Three-Year Results from Two Randomised Phase 3 Studies (CIMPASI-1 and CIMPASI-2)

Dermatology and therapy, 2023-06, Vol.13 (6), p.1389-1390

2023

Volltextzugriff (PDF)

Chronic corticosterone manipulations in mice affect brain cell proliferation rates, but only partly affect BDNF protein levels

Neuroscience letters, 2006-03, Vol.396 (1), p.12-16

2006

Volltextzugriff (PDF)

Insurmountable angiotensin AT1 receptor antagonists : the role of tight antagonist binding

European journal of pharmacology, 1999-05, Vol.372 (2), p.199-206

1999

Volltextzugriff (PDF)

A two-state receptor model for the interaction between angiotensin II type 1 receptors and non-peptide antagonists

Biochemical pharmacology, 2001-02, Vol.61 (3), p.277-284

2001

Volltextzugriff (PDF)

Angiotensin II type 1 receptor antagonists: Why do some of them produce insurmountable inhibition?

Biochemical pharmacology, 2000-12, Vol.60 (11), p.1557-1563

2000

Volltextzugriff (PDF)

Distinct binding properties of the AT1 receptor antagonist [3H]candesartan to intact cells and membrane preparations

Biochemical pharmacology, 2002-04, Vol.63 (7), p.1273-1279

2002

Volltextzugriff (PDF)

Reversible and syntopic interaction between angiotensin receptor antagonists on Chinese hamster ovary cells expressing human angiotensin II type 1 receptors

Biochemical pharmacology, 2000-04, Vol.59 (8), p.927-935

2000

Volltextzugriff (PDF)

Molecular characterization of the high-affinity [3H]neuropeptide Y-binding component from the venom of Conus anemone

Fundamental & clinical pharmacology, 2003-08, Vol.17 (4), p.457-462

2003

Volltextzugriff (PDF)

Gene expression profiles highlight adaptive brain mechanisms in corticotropin releasing factor overexpressing mice

Brain research. Molecular brain research., 2004-10, Vol.129 (1), p.135-150

2004

Volltextzugriff (PDF)

A dynamic model of pneumococcal infection in the United States: Implications for prevention through vaccination

Vaccine, 2010-05, Vol.28 (21), p.3650-3660

2010

Volltextzugriff (PDF)

Long-lasting angiotensin type 1 receptor binding and protection by candesartan: comparison with other biphenyl-tetrazole sartans

Journal of hypertension, 2006-03, Vol.24 Suppl 1 (1), p.S23-S30

2006

Volltextzugriff (PDF)

Distinctions between non-peptide angiotensin II AT1-receptor antagonists

Journal of the renin-angiotensin-aldosterone system, 2001-03, Vol.2 (1_suppl), p.S24-S31

2001

Volltextzugriff (PDF)

Inhibition of angiotensin II-induced inositol phosphate production by triacid nonpeptide antagonists in CHO cells expressing human AT1 receptors

Pharmaceutical research, 2000-12, Vol.17 (12), p.1482-1488

2000

Volltextzugriff (PDF)

Binding characteristics of [3H]-irbesartan to human recombinant angiotensin type 1 receptors

Journal of the renin-angiotensin-aldosterone system, 2000-06, Vol.1 (2), p.159-165

2000

Volltextzugriff (PDF)

Role of basic amino acids of the human angiotensin type 1 receptor in the binding of the non-peptide antagonist candesartan

Journal of the renin-angiotensin-aldosterone system, 2001-03, Vol.2 (1_suppl), p.S32-S36

2001

Volltextzugriff (PDF)

Insurmountable AT1 receptor antagonism: the need for different antagonist binding states of the receptor

Trends in pharmacological sciences (Regular ed.), 2001-07, Vol.22 (7), p.343-344

2001

Volltextzugriff (PDF)

Binding of the antagonist [3H]candesartan to angiotensin II AT1 receptor-tranfected Chinese hamster ovary cells

European journal of pharmacology, 1999-02, Vol.367 (2-3), p.413-422

1999

Volltextzugriff (PDF)

Distinct binding properties of the AT(1) receptor antagonist [(3)H]candesartan to intact cells and membrane preparations

Biochemical pharmacology, 2002-04, Vol.63 (7), p.1273-1279

2002

Volltextzugriff (PDF)

Insurmountable AT 1 receptor antagonism: the need for different antagonist binding states of the receptor

Trends in pharmacological sciences (Regular ed.), 2001, Vol.22 (7), p.343-344

2001

Volltextzugriff (PDF)

Angiotensin II type 1 receptor antagonists

Biochemical pharmacology, 2000-12, Vol.60 (11), p.1557-1563

2000

Volltextzugriff (PDF)

1 – 25 von 51

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(51)
Mit Volltextzugriff
(50)

Publikationsform

Artikel
(51)

Sprache

Englisch
(51)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Hexavalent vaccines: increasing options for policy-makers and providers. A review of the data supporting interchangeability (substitution with vaccines containing fewer antigens) and mixed schedules from the same manufacturer

Treatment Preferences in Young Adults with Moderate to Severe Psoriasis: A Qualitative Study from the Nordic Countries

Certolizumab Pegol for the Treatment of Plaque Psoriasis in Routine Clinical Practice: One-Year Results from the CIMREAL Study

Correction: Certolizumab Pegol for the Treatment of Plaque Psoriasis in Routine Clinical Practice: One-Year Results from the CIMREAL Study

Long-Term Health-Related Quality of Life in Patients with Plaque Psoriasis Treated with Certolizumab Pegol: Three-Year Results from Two Randomised Phase 3 Studies (CIMPASI-1 and CIMPASI-2)

Publisher Correction: Long-Term Health-Related Quality of Life in Patients with Plaque Psoriasis Treated with Certolizumab Pegol: Three-Year Results from Two Randomised Phase 3 Studies (CIMPASI-1 and CIMPASI-2)

Chronic corticosterone manipulations in mice affect brain cell proliferation rates, but only partly affect BDNF protein levels

Insurmountable angiotensin AT1 receptor antagonists : the role of tight antagonist binding

A two-state receptor model for the interaction between angiotensin II type 1 receptors and non-peptide antagonists

Angiotensin II type 1 receptor antagonists: Why do some of them produce insurmountable inhibition?

Distinct binding properties of the AT1 receptor antagonist [3H]candesartan to intact cells and membrane preparations

Reversible and syntopic interaction between angiotensin receptor antagonists on Chinese hamster ovary cells expressing human angiotensin II type 1 receptors

Molecular characterization of the high-affinity [3H]neuropeptide Y-binding component from the venom of Conus anemone

Gene expression profiles highlight adaptive brain mechanisms in corticotropin releasing factor overexpressing mice

A dynamic model of pneumococcal infection in the United States: Implications for prevention through vaccination

Long-lasting angiotensin type 1 receptor binding and protection by candesartan: comparison with other biphenyl-tetrazole sartans

Distinctions between non-peptide angiotensin II AT1-receptor antagonists

Inhibition of angiotensin II-induced inositol phosphate production by triacid nonpeptide antagonists in CHO cells expressing human AT1 receptors

Binding characteristics of [3H]-irbesartan to human recombinant angiotensin type 1 receptors

Role of basic amino acids of the human angiotensin type 1 receptor in the binding of the non-peptide antagonist candesartan

Insurmountable AT1 receptor antagonism: the need for different antagonist binding states of the receptor

Binding of the antagonist [3H]candesartan to angiotensin II AT1 receptor-tranfected Chinese hamster ovary cells

Distinct binding properties of the AT(1) receptor antagonist [(3)H]candesartan to intact cells and membrane preparations

Insurmountable AT 1 receptor antagonism: the need for different antagonist binding states of the receptor

Angiotensin II type 1 receptor antagonists

Suchergebnisse filtern